A Phase II Study of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Samsung Medical Center
- 08 Apr 2017 Status changed from not yet recruiting to recruiting.
- 08 Apr 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 05 Nov 2014 New trial record